AR055100A1 - Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato - Google Patents

Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato

Info

Publication number
AR055100A1
AR055100A1 ARP060103273A ARP060103273A AR055100A1 AR 055100 A1 AR055100 A1 AR 055100A1 AR P060103273 A ARP060103273 A AR P060103273A AR P060103273 A ARP060103273 A AR P060103273A AR 055100 A1 AR055100 A1 AR 055100A1
Authority
AR
Argentina
Prior art keywords
alkylene
group
nr6r7
alkyl
independently selected
Prior art date
Application number
ARP060103273A
Other languages
English (en)
Inventor
Methvin Isaac
Malik Slassi
Ian Egle
Fupeng Ma
Original Assignee
Astrazeneca Ab
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Nps Pharma Inc filed Critical Astrazeneca Ab
Publication of AR055100A1 publication Critical patent/AR055100A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1): en donde A se selecciona del grupo formado por CR8R9, NR5, O, S, SO y SO2, B se selecciona del grupo formado por CH y N; D se selecciona del grupo formado por NH, N-C1-6-alquilo, y -(CR5R6)z-, en donde uno de los grupos -CR5R6- se puede reemplazar por -C(O)-, NH, o NC1-6-alquilo; L se selecciona del grupo formado por un enlace directo y -(CR5R6)w-, en donde cuando L es -(CR5R6)w; (i) B-L pueden ser insaturados, o dos átomos de carbono adyacentes pueden formar parte de un anillo ciclopropilo; o (ji) uno o dos grupos CR5R6 se puede reemplazar con O, S, o NR5; el resto de formula (2) representa un anillo seleccionado entre el grupo formado por azetidina y un anillo de 5 a 7 miembros, que pueden ser insaturados, en donde el anillo puede estar sustituido por uno o más R4; R1en cada caso, se selecciona del grupo formado por H, F, Cl, Br, I, OH, CN, nitro, C1-6-alquilo, OC1-6-alquilo, C1-6-alquilhalo, OC1-6-alquilhalo, C2-6-alquenilo, OC2-6-alquenilo, C2-6-alquinilo, OC2-6-alquinilo, C3-8-cicloalquilo, C1-6-alquilen-C3-8-cicloalquilo, OC0-6- alquilen-C3-8-cicloalquilo, arilo, heteroarilo, C1-6-alquilenoarilo, C1-6-alquilenoheteroarilo, OC1-6- alquilenoarilo, OC1-6- alquilenoheteroarilo, C1-6-alquilenoheterocicloalquilo, (CO) R5, (CO)OR5, C1-6-alquilenoOR5, OC2-6-alquilenoOR5, C1-6-alquileno (CO)R5, OC1-6-alquileno(CO)R5, C1-6-alquilenociano, OC2-6-alquilenociano, C0-6-alquilenoNR6R7, OC2-6-alquilenoNR6R7, C1-6- alquileno(CO)NR6R7, OC1-6-alquileno(CO) NR6R7, C0-6-alquilenoNR6(CO)R7, OC2-6-alquilenoNR6(CO)R7, C0-6-alquilenoNR6(CO)NR6R7, C0-6-alquilenoSO2R5, OC2-6-alquilenoSO2R5, C0--6-alquileno (SO2) NR6R7, OC2-6-alquileno (SO2)NR6R7, C0-6-alquilenoNR6 (SO2)R7, OC2-6-alquilenoNR6 (SO2)R7', C0-6- alquilenoNR6(SO2)NR6R7, OC2-6-alquilenoNR6(SO2)NR6R7, (CO)NR6R7 y SO3R5, en donde cualquier grupo cíclico puede estar también sustituido con uno o más grupos R2; R2 y R4, en cada caso, se seleccionan en forma independiente entre el grupo formado por H, F, Cl, Br, I, CN, nitro, hidroxi, oxo, C1-6-alquilo, OC1-6-alquilo, C1-6-alquilhalo, OC1-6-alquilhalo y C0-6-alquilenoNR5R6; R3 es un sistema de anillo de 5 a 12 miembros que es opcionalmente sustituido por hasta tres grupos R1, en donde el sistema de anillo puede contener uno o más heteroátomos seleccionados en forma independiente entre el grupo formado por N, O y S; R5 se selecciona del grupo formado por H, C1-6-alquilo, arilo, C3-8- cicloalquilo, C1-6-alquilenoarilo y C1-6-alquilen-C3-8-cicloalquilo, en donde cualquier grupo cíclico puede estar también sustituido con uno o más grupos R2 seleccionados en forma independiente; R6 y R7 se seleccionan en forma independiente entre el grupo formado por H, y C1-6- alquilo; R8 y R9 se seleccionan en forma independiente entre el grupo formado por H, -O-(CH2)2-O- y -O-(CH2)3-O-; m y n son enteros seleccionados en forma independiente entre el grupo formado por 0, 1, 2, 3 y 4, con la salvedad de que m y n no pueden ser simultáneamente 0; x y y son enteros seleccionados en forma independiente entre el grupo formado por 1, 2, y 3; y w y z'. son enteros seleccionados en forma independiente entre el grupo formado por 1, 2, 3, 4, 5, y 6; o una sal aceptable para uso farmacéutico, hidrato, solvato, isoforma, tautomero, isomero optico, o combinacion de los mismos.
ARP060103273A 2005-08-05 2006-07-28 Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato AR055100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70547105P 2005-08-05 2005-08-05

Publications (1)

Publication Number Publication Date
AR055100A1 true AR055100A1 (es) 2007-08-08

Family

ID=37607094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103273A AR055100A1 (es) 2005-08-05 2006-07-28 Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato

Country Status (17)

Country Link
US (2) US20080318999A1 (es)
EP (1) EP1912989A2 (es)
JP (1) JP2009503069A (es)
KR (1) KR20080035576A (es)
CN (1) CN101268077A (es)
AR (1) AR055100A1 (es)
AU (1) AU2006279034A1 (es)
BR (1) BRPI0614168A2 (es)
CA (1) CA2616020A1 (es)
EC (1) ECSP088128A (es)
IL (1) IL188809A0 (es)
MX (1) MX2008001152A (es)
NO (1) NO20080475L (es)
RU (1) RU2008101923A (es)
TW (1) TW200745112A (es)
UY (1) UY29710A1 (es)
WO (1) WO2007018998A2 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
EP1963268B1 (en) * 2005-12-07 2010-12-01 NSAB, Filial af NeuroSearch Sweden AB, Sverige Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
JP2010525073A (ja) * 2007-04-23 2010-07-22 ハウス イアー インスティトゥート 代謝型グルタミン酸受容体７の調節による老人性難聴の治療及び／又は予防
CA2698929C (en) 2007-09-14 2016-01-19 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
PL2203439T3 (pl) * 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
WO2009033702A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
US8785486B2 (en) * 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20110065669A1 (en) * 2008-05-15 2011-03-17 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
AU2009246626A1 (en) * 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
AU2009260469B2 (en) * 2008-05-29 2014-02-13 Albany Molecular Research, Inc. 5-HT3 receptor modulators, methods of making, and use thereof
US20110171134A1 (en) * 2008-06-25 2011-07-14 Iskandar Bermans J (6s)-5-methyltetrahydrofolic acid for therapy of tissue injury
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
JP2012503658A (ja) * 2008-09-26 2012-02-09 メルク・シャープ・エンド・ドーム・コーポレイション オキサゾロベンゾイミダゾール誘導体
MX2011003691A (es) 2008-10-16 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
ES2401691T3 (es) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
AU2010246607B2 (en) 2009-05-12 2012-09-27 Addex Pharma S.A. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JP5634506B2 (ja) 2009-05-12 2014-12-03 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
GB201220157D0 (en) * 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
CN102964292A (zh) * 2012-11-26 2013-03-13 盛世泰科生物医药技术(苏州)有限公司 4-（2-（三氟甲氧基）苯基）哌啶的合成
CA2903881C (en) * 2013-03-15 2021-05-18 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR101672096B1 (ko) * 2013-09-30 2016-11-02 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 발광 소자
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
KR20220038826A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015154047A1 (en) * 2014-04-03 2015-10-08 Restorgenex Corporation Novel methods
SG10201809353TA (en) 2014-04-23 2018-11-29 Incyte Corp 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
US9975906B2 (en) 2014-05-16 2018-05-22 Shionogi & Co., Ltd. Tricyclic heterocycle derivatives having HIV replication inhibitory effect
TWI712603B (zh) 2014-09-15 2020-12-11 美商英塞特公司 作為ｂｅｔ蛋白抑制劑之三環雜環
MX2017015256A (es) 2015-05-29 2018-02-19 Shionogi & Co Derivados triciclicos que contienen nitrogeno que tienen actividad inhibidora de la replicacion del virus de inmunodeficiencia adquirida (vih).
WO2017042182A1 (en) 2015-09-08 2017-03-16 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
IL257743B (en) 2015-09-17 2022-08-01 Marvin J Miller Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
WO2017222977A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
DK3347352T3 (da) 2016-08-19 2019-08-26 Gilead Sciences Inc Terapeutiske forbindelser anvendelige til profylaktisk eller terapeutisk behandling af en hiv-virusinfektion
ES2958828T3 (es) 2018-02-15 2024-02-15 Gilead Sciences Inc Derivados de piridina y su uso para tratar una infección por VIH
TWI823164B (zh) 2018-02-16 2023-11-21 美商基利科學股份有限公司 用於製備有療效化合物之方法及中間物
TW202019408A (zh) * 2018-06-28 2020-06-01 美商永恒生物科技公司 稠合三環雜環化合物及其治療用途
AU2019307500B2 (en) 2018-07-16 2022-09-29 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
WO2020151682A1 (zh) * 2019-01-23 2020-07-30 成都先导药物开发股份有限公司 一种大环类免疫调节剂
EP3938340B1 (en) * 2019-03-11 2025-07-09 Collaborative Medicinal Development, LLC Heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN116283758B (zh) * 2023-03-30 2024-05-24 安徽工业大学 一种喹啉合成n-甲酰基四氢喹啉的方法及产品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
CZ294493B6 (cs) * 2000-08-08 2005-01-12 Sanofi-Synthelabo Deriváty benzimidazolu, způsob jejich přípravy a léčebné prostředky s jejich obsahem
EP1339402B1 (en) * 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors

Also Published As

Publication number Publication date
KR20080035576A (ko) 2008-04-23
TW200745112A (en) 2007-12-16
JP2009503069A (ja) 2009-01-29
WO2007018998A2 (en) 2007-02-15
BRPI0614168A2 (pt) 2017-07-25
MX2008001152A (es) 2008-04-02
CN101268077A (zh) 2008-09-17
EP1912989A2 (en) 2008-04-23
CA2616020A1 (en) 2007-02-15
WO2007018998A3 (en) 2007-05-03
US20080318999A1 (en) 2008-12-25
UY29710A1 (es) 2007-02-28
IL188809A0 (en) 2008-08-07
NO20080475L (no) 2008-04-15
RU2008101923A (ru) 2009-09-10
US20070032469A1 (en) 2007-02-08
ECSP088128A (es) 2008-02-20
AU2006279034A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
AR055100A1 (es) Benzimidazoles triciclicos y su uso como moduladores de receptores metabotropicos de glutamato
PE20040909A1 (es) Derivados fluoroglicosidos aromaticos con afinidad por el receptor sglt2
NI200700270A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
CO5640084A2 (es) Ligandos de receptores cannabinoides y sus usos
AR058699A1 (es) Derivados de sulfonamidoanilina como inhibidores de tirosina-quinasas jak-2 y jak-3
CO6241123A2 (es) Moduladores de la gamma secretasa
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
AR122973A1 (es) Compuestos de piperidina sustituida y su uso
CO6220949A2 (es) Derivados pirazolicos como inhibidores de la 11 beta -hsd1
CO5690548A2 (es) N-arilheterociclos sustituidos, procedimientos para su preparacion y su empleo como medicamentos
CR9980A (es) Imidazolinas 4,4,5,5 tetrasustituidas
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
PE20160548A1 (es) Sulfonamidas como moduladores de canales de sodio
ECSP055636A (es) Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa
CR10383A (es) Derivados triazolopirazina.
BR112014007912A2 (pt) derivados de pirazoloquinolina
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
AR064517A1 (es) Pirimidinionas biciclicas y sus usos
AR057728A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotropicos. composiciones farmaceuticas.
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO6170405A2 (es) Composicion plaguicida que comprende fluopicolida y un compuesto insecticida
AR037906A1 (es) Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
FB Suspension of granting procedure